Skip to main content
Log in

Tamoxifen, raloxifene worthwhile for high breast-cancer risk

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Kondo M, Hoshi S-L, Toi M.Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. British Journal of Cancer 100: 281-290, No. 2, 27 Jan 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamoxifen, raloxifene worthwhile for high breast-cancer risk. Pharmacoecon. Outcomes News 573, 6 (2009). https://doi.org/10.2165/00151234-200905730-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905730-00018

Keywords

Navigation